ContraFect (NASDAQ:CFRX) Shares Cross Below 200 Day Moving Average of $5.48

Shares of ContraFect Co. (NASDAQ:CFRX – Get Rating) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.48 and traded as low as $1.54. ContraFect shares last traded at $1.55, with a volume of 91,075 shares.

Wall Street Analyst Weigh In

CFRX has been the subject of a number of analyst reports. Maxim Group upgraded ContraFect from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Thursday, April 13th. StockNews.com downgraded ContraFect from a “hold” rating to a “sell” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $180.75.

ContraFect Stock Down 3.4 %

The stock has a market capitalization of $2.23 million, a PE ratio of -0.02 and a beta of 0.44. The company has a 50-day moving average of $1.66 and a 200 day moving average of $5.37.

ContraFect (NASDAQ:CFRX – Get Rating) last issued its earnings results on Friday, March 31st. The biotechnology company reported ($16.14) earnings per share (EPS) for the quarter. As a group, equities analysts predict that ContraFect Co. will post -15.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of ContraFect by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after acquiring an additional 11,064 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of ContraFect by 1.2% in the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock worth $1,486,000 after buying an additional 4,948 shares during the period. State Street Corp boosted its position in shares of ContraFect by 33.5% in the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of ContraFect by 62.9% in the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock worth $412,000 after buying an additional 43,564 shares during the period. Finally, Armistice Capital LLC purchased a new stake in shares of ContraFect in the fourth quarter worth about $393,000. Hedge funds and other institutional investors own 27.34% of the company’s stock.

ContraFect Company Profile

(Get Rating)

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.